Surrozen (SRZN) Return on Capital Employed (2021 - 2026)
Surrozen (SRZN) posted quarterly Return on Capital Employed of 42.93% for Q1 2026, down 640.0% year-over-year from 7.95% in Q1 2025, and up 11.82% quarter-over-quarter from 48.69% in Q4 2025.
Surrozen (SRZN) Return on Capital Employed (2021 - 2026) Analysis & Trends
Surrozen's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 42.93% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 640.0% year-over-year to 42.93%; the TTM figure through Mar 2026 stood at 42.93% (down 640.0% YoY), while the FY2025 annual figure was 66.11%, down 220.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 42.93%, up from 48.69% in the prior quarter.
- The five-year high for Return on Capital Employed was 25.17% in Q2 2025, with the low at 114.48% in Q1 2024.
- The 5-year median for Return on Capital Employed is 60.03% (2023), against an average of 63.3%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed sank 5445 bps in 2024, then soared 8681 bps in 2025.
- Surrozen's Return on Capital Employed stood at 54.94% in 2022, then plunged by 94 bps to 106.77% in 2023, then surged by 42 bps to 62.42% in 2024, then climbed by 22 bps to 48.69% in 2025, then advanced by 12 bps to 42.93% in 2026.
- Business Quant data shows SRZN's Return on Capital Employed at 42.93% in Q1 2026, 48.69% in Q4 2025, and 41.42% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | -40.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.63% |
| Mar 31, 2026 | -42.93% |
| Dec 31, 2025 | -48.69% |
| Sep 30, 2025 | -41.42% |
| Jun 30, 2025 | -25.17% |
| Mar 31, 2025 | -36.53% |
| Dec 31, 2024 | -62.42% |
| Sep 30, 2024 | -65.99% |
| Jun 30, 2024 | -111.98% |
| Mar 31, 2024 | -114.48% |
| Dec 31, 2023 | -106.77% |
| Sep 30, 2023 | -73.07% |
| Jun 30, 2023 | -64.87% |
| Mar 31, 2023 | -60.03% |
| Dec 31, 2022 | -54.94% |
| Sep 30, 2022 | -64.14% |
| Jun 30, 2022 | -55.94% |
| Mar 31, 2022 | -46.82% |
| Dec 31, 2021 | -41.73% |
| Sep 30, 2021 | -36.46% |